For the interpretation of the principles and guidelines of good manufacturing practice, the manufacturers and the competent authorities shall take into account the detailed guidelines referred to in the second paragraph of Article 47 of Directive 2001/83/EC, published by the Commission in the %quot%Guide to good manufacturing practice for medicinal products and for investigational medicinal products%quot%.
Article 4 Conformity with good manufacturing practice 1.
The manufacturer shall ensure that manufacturing operations are carried out in accordance with good manufacturing practice and with the manufacturing authorisation.
Article 5 Compliance with marketing authorisation 1.
The manufacturer shall ensure that all manufacturing operations for medicinal products subject to a marketing authorisation are carried out in accordance with the information provided in the application for marketing authorisation as accepted by the competent authorities.
In the case of investigational medicinal products, the manufacturer shall ensure that all manufacturing operations are carried out in accordance with the information provided by the sponsor pursuant to Article 9(2) of Directive 2001/20/EC as accepted by the competent authorities. 2.
Article 6 Quality assurance system The manufacturer shall establish and implement an effective pharmaceutical quality assurance system, involving the active participation of the management and personnel of the different departments.
Organisation charts and job descriptions shall be approved in accordance with the manufacturer's internal procedures. 3.
The staff referred to in paragraph 2 shall be given sufficient authority to discharge their responsibility correctly. 4.
Article 8 Premises and equipment 1.
Article 11 Quality control 1.
For medicinal products, including those imported from third countries, contract laboratories may be used if authorised in accordance with Article 12 of this Directive and point (b) of Article 20 of Directive 2001/83/EC.
Article 12 Work contracted out 1.
Any manufacturing operation or operation linked thereto which is carried out under contract shall be the subject of a written contract. 2.
The contract-acceptor shall comply with the principles and guidelines of good manufacturing practice and shall submit to inspections carried out by the competent authorities pursuant to Article 111 of Directive 2001/83/EC and Article 15 of Directive 2001/20/EC.
Article 13 Complaints, product recall and emergency unblinding 1.
Any complaint concerning a defect shall be recorded and investigated by the manufacturer.
Any recall shall be made in accordance with the requirements referred to in Article 123 of Directive 2001/83/EC. 2.
The sponsor shall implement a procedure for the rapid unblinding of blinded products, where this is necessary for a prompt recall as referred to in paragraph 2.
Article 14 Self-inspection The manufacturer shall conduct repeated self-inspections as part of the quality assurance system in order to monitor the implementation and respect of good manufacturing practice and to propose any necessary corrective measures.
Article 15 Labelling In the case of an investigational medicinal product, labelling shall be such as to ensure protection of the subject and traceability, to enable identification of the product and trial, and to facilitate proper use of the investigational medicinal product.
Article 16 Repeal of Directive 91/356/EEC Directive 91/356/EEC is repealed.
The Member States shall determine how such reference is to be made. 2.
Article 18 Entry into force This Directive shall enter into force on the 20th day following that of its publication in the Official Journal of the European Union.
Article 19 Addressees This Directive is addressed to the Member States.
Done at Brussels, 8 October 2003.
For the Commission Erkki Liikanen Member of the Commission (1) OJ L 311, 28.11.2001, p. 67. (2) OJ L 159, 27.6.2003, p. 46. (3) OJ L 193, 17.7.1991, p. 30. (4) OJ L 121, 1.5.2001, p. 34.
